Laurus Labs Ltd
LAUL.IN
$5.21
Closing
▲0.30%
1D
▲0.98%
YTD
Market cap
$2.81B
52 week high
$5.65
52 week low
$3.35
Volume
730,062
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$2.81B
Analysts' Rating
HOLD
Price Target (Mean)
Unable to collect data for some field(s).
Total Analysts
1
P/E
124.98
Operating Margin
7.72%
Beta
1.51
Revenue Growth (Annual)
13.59%
52 week high
$5.65
52 week low
$3.35
Div. Yield
0.37%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
